298 related articles for article (PubMed ID: 14962259)
1. Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and allogeneic stem cell transplantation.
Rabitsch W; Prinz E; Ackermann J; Wöhrer S; Kaufmann H; Seidl S; Keil F; Kalhs P; Greinix H; Gisslinger H; Leitner G; Drach J
Eur J Haematol; 2004 Jan; 72(1):26-31. PubMed ID: 14962259
[TBL] [Abstract][Full Text] [Related]
2. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
Kröger N; Einsele H; Wolff D; Casper J; Freund M; Derigs G; Wandt H; Schäfer-Eckart K; Wittkowsky G; Schmitz N; Krüger W; Zabelina T; Renges H; Ayuk F; Krüll A; Zander A;
Bone Marrow Transplant; 2003 Jun; 31(11):973-9. PubMed ID: 12774047
[TBL] [Abstract][Full Text] [Related]
3. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma.
Cavo M; Bandini G; Benni M; Gozzetti A; Ronconi S; Rosti G; Zamagni E; Lemoli RM; Bonini A; Belardinelli A; Motta MR; Rizzi S; Tura S
Bone Marrow Transplant; 1998 Jul; 22(1):27-32. PubMed ID: 9678792
[TBL] [Abstract][Full Text] [Related]
4. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
Giralt S; Aleman A; Anagnostopoulos A; Weber D; Khouri I; Anderlini P; Molldrem J; Ueno NT; Donato M; Korbling M; Gajewski J; Alexanian R; Champlin R
Bone Marrow Transplant; 2002 Sep; 30(6):367-73. PubMed ID: 12235521
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission.
Byrne JL; Fairbairn J; Davy B; Carter IG; Bessell EM; Russell NH
Bone Marrow Transplant; 2003 Feb; 31(3):157-61. PubMed ID: 12621475
[TBL] [Abstract][Full Text] [Related]
7. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
9. Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions induced.
van Dorp S; Meijer E; van de Donk NW; Dekker AW; Nieuwenhuis K; Minnema MC; Petersen E; Schutgens R; Verdonck LF; Lokhorst HM
Neth J Med; 2007 May; 65(5):178-84. PubMed ID: 17519513
[TBL] [Abstract][Full Text] [Related]
10. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
Martino M; Console G; Irrera G; Praticò G; Stelitano C; Callea V; Morabito F; Quartarone E; Musolino C; Piro E; Brugiatelli M; Iacopino P
Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
[TBL] [Abstract][Full Text] [Related]
11. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
12. Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation.
Hunter HM; Peggs K; Powles R; Rahemtulla A; Mahendra P; Cavenagh J; Littlewood T; Potter M; Hunter A; Pagliuca A; Williams CD; Cook G; Towlson K; Marks David I; Russell NH;
Br J Haematol; 2005 Feb; 128(4):496-502. PubMed ID: 15686458
[TBL] [Abstract][Full Text] [Related]
13. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma.
Bruno B; Sorasio R; Patriarca F; Montefusco V; Guidi S; Busca A; Scimé R; Console G; Milone G; Marotta G; Dominietto A; Giaccone L; Rotta M; Falda M; Bacigalupo A; Bosi A; Corradini P; Fanin R; Pollichieni S; Boccadoro M;
Eur J Haematol; 2007 Apr; 78(4):330-7. PubMed ID: 17331132
[TBL] [Abstract][Full Text] [Related]
14. Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma.
Cogle CR; Moreb JS; Leather HL; Finiewicz KJ; Khan SA; Reddy VS; Wingard JR
Am J Hematol; 2003 Jul; 73(3):169-75. PubMed ID: 12827653
[TBL] [Abstract][Full Text] [Related]
15. Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients.
Kim HJ; Park CY; Park YH; Kim YJ; Kim DW; Min WS; Kim CC
Bone Marrow Transplant; 2003 Jan; 31(2):79-86. PubMed ID: 12621487
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.
Eom KS; Min CK; Lee S; Kim YJ; Kim SY; Kim HJ; Lee JW; Min WS; Kim CC
Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727
[TBL] [Abstract][Full Text] [Related]
17. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma.
Majolino I; Corradini P; Scimè R; Santoro A; Tarella C; Cavallaro AM; Palumbo A; Indovina A; Caracciolo D; Boccadoro M; Marcenò R; Pileri A
Bone Marrow Transplant; 1998 Sep; 22(5):449-55. PubMed ID: 9733268
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.
Ayuk F; Perez-Simon JA; Shimoni A; Sureda A; Zabelina T; Schwerdtfeger R; Martino R; Sayer HG; Alegre A; Lahuerta JJ; Atanackovic D; Wolschke C; Nagler A; Zander AR; San Miguel JF; Kröger N
Haematologica; 2008 Sep; 93(9):1343-50. PubMed ID: 18641030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]